Journey Medical Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

LICENSES ACQUIRED (Details)

LICENSES ACQUIRED (Details) - USD ($) $ in Thousands		1 Months Ended			6 Months Ended
LICENSES ACQUIRED (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Jul. 31, 2020	Jun. 30, 2023	Jun. 30, 2022
LICENSES/PRODUCTS ACQUIRED
Payments to Acquire Productive Assets					$ 5,000	$ 20,000
D F D Agreement \| Minimum
LICENSES/PRODUCTS ACQUIRED
Percentage of royalties payable on net sales		10.00%
D F D Agreement \| Maximum
LICENSES/PRODUCTS ACQUIRED
Threshold additional contingent regulatory and commercial milestone payments payable		$ 158,000
Percentage of royalties payable on net sales		15.00%
Asset purchase agreement \| Qbrexza
LICENSES/PRODUCTS ACQUIRED
Age of patients	9 years
Percentage of diminution in royalty			50.00%
Asset purchase agreement \| Royalty payment percentage for first two years \| Qbrexza
LICENSES/PRODUCTS ACQUIRED
Period of royalty payments	2 years
Asset purchase agreement \| Royalty payment percentage for eight years thereafter \| Qbrexza
LICENSES/PRODUCTS ACQUIRED
Term of royalty			8 years
Asset purchase agreement \| Minimum \| Royalty payment percentage for first two years \| Qbrexza
LICENSES/PRODUCTS ACQUIRED
Percent of royalty payments			30.00%
Asset purchase agreement \| Minimum \| Royalty payment percentage for eight years thereafter \| Qbrexza
LICENSES/PRODUCTS ACQUIRED
Percent of royalty payments			12.00%
Asset purchase agreement \| Maximum \| Royalty payment percentage for first two years \| Qbrexza
LICENSES/PRODUCTS ACQUIRED
Percent of royalty payments			40.00%
Asset purchase agreement \| Maximum \| Royalty payment percentage for eight years thereafter \| Qbrexza
LICENSES/PRODUCTS ACQUIRED
Percent of royalty payments			19.00%
Asset purchase agreement \| Eli Lilly and Company \| Qbrexza
LICENSES/PRODUCTS ACQUIRED
Upfront fees			$ 12,500
Milestone payments payable	$ 144,000		$ 144,000
License and supply agreement With DRL \| Accutane
LICENSES/PRODUCTS ACQUIRED
Threshold additional contingent regulatory and commercial milestone payments payable				$ 3,000
Upfront fees				1,000
Milestone payments payable				4,000
Amount of expense agreed to pay under the agreement				5,000
Contingent amount payable				$ 17,000
Renewable Mutual Agreement Term				10 years
Termination Written Notice Period To Other Party				180 days